Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kin...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.651541/full |
id |
doaj-8bfabd0a2358476b88a0a6a8fb02e4eb |
---|---|
record_format |
Article |
spelling |
doaj-8bfabd0a2358476b88a0a6a8fb02e4eb2021-05-26T06:53:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.651541651541Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular MechanismsBin Wang0Rui Li1Shuai Wu2Xin Liu3Jianlin Ren4Jing Li5Kaixin Bi6Yanhong Wang7Hongyan Jia8Department of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaDepartment of Microbiology and Immunology, Shanxi Medical University, Taiyuan, ChinaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, ChinaBreast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kinases 4/6CDK4/6inhibitors have shown good clinical activity in treating breast cancer. Nevertheless, despite the promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the benefits of this novel target therapy. In the present review, we provide an overview of the currently known molecular mechanisms of resistance to CDK4/6 inhibitors, and discuss the potential strategies to overcoming drug resistance improving the outcomes for breast cancer patients treated with CDK4/6 inhibitors.https://www.frontiersin.org/articles/10.3389/fonc.2021.651541/fullbreast cancerCDK4/6 inhibitorsdrug resistancemolecular mechanismscombination administration |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bin Wang Rui Li Shuai Wu Xin Liu Jianlin Ren Jing Li Kaixin Bi Yanhong Wang Hongyan Jia |
spellingShingle |
Bin Wang Rui Li Shuai Wu Xin Liu Jianlin Ren Jing Li Kaixin Bi Yanhong Wang Hongyan Jia Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms Frontiers in Oncology breast cancer CDK4/6 inhibitors drug resistance molecular mechanisms combination administration |
author_facet |
Bin Wang Rui Li Shuai Wu Xin Liu Jianlin Ren Jing Li Kaixin Bi Yanhong Wang Hongyan Jia |
author_sort |
Bin Wang |
title |
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms |
title_short |
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms |
title_full |
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms |
title_fullStr |
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms |
title_full_unstemmed |
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms |
title_sort |
breast cancer resistance to cyclin-dependent kinases 4/6 inhibitors: intricacy of the molecular mechanisms |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-05-01 |
description |
Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kinases 4/6CDK4/6inhibitors have shown good clinical activity in treating breast cancer. Nevertheless, despite the promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the benefits of this novel target therapy. In the present review, we provide an overview of the currently known molecular mechanisms of resistance to CDK4/6 inhibitors, and discuss the potential strategies to overcoming drug resistance improving the outcomes for breast cancer patients treated with CDK4/6 inhibitors. |
topic |
breast cancer CDK4/6 inhibitors drug resistance molecular mechanisms combination administration |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.651541/full |
work_keys_str_mv |
AT binwang breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms AT ruili breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms AT shuaiwu breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms AT xinliu breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms AT jianlinren breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms AT jingli breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms AT kaixinbi breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms AT yanhongwang breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms AT hongyanjia breastcancerresistancetocyclindependentkinases46inhibitorsintricacyofthemolecularmechanisms |
_version_ |
1721426423419240448 |